ClinicalTrials.gg
CompletedNCT05011305NASHUpdated Sep 21, 2026

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

A Phase 2 interventional study of Saroglitazar Magnesium 2 mg and Saroglitazar Magnesium 4 mg in Nonalcoholic Steatohepatitis and Fibrosis, sponsored by Zydus Therapeutics Inc.. Completed at 129 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
83rd of 460
189 · median 56
Started
2021
with 56 others
Phase 2
192 of 547
15 open now
Registered
409th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 83rd largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 409th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

Read the detailed description

A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis.

03

Conditions studied

  • Nonalcoholic Steatohepatitis
  • Fibrosis

Keywords

  • Saroglitazar Magnesium
  • Nonalcoholic Steatohepatitis
  • NASH
  • Fibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, between 18 and 75 years of age, both inclusive at screening.
  • ≤45 kg/m²
  • Histological confirmation of NASH with liver fibrosis by central pathologist on a diagnostic liver with a NAS ≥4 with at least one-point score in each of the three components of the NAFLD activity score [NAS] (steatosis scored 0-3, ballooning degeneration scored 0-2, and lobular inflammation scored 0-3) and NASH by pattern recognition Note: The biopsy must not have been performed more than 24 weeks before randomization.
  • The subjects must have a stable body weight (no more than 5% change) between the time of biopsy and randomization.
  • Fibrosis stage 2 and 3, according to the NASH CRN fibrosis staging, reported by central pathologist.
  • If the subjects have type 2 diabetes mellitus, then it must be moderately controlled with ≤ 9.5% and on a stable dose of permitted anti-diabetic medication for at least 90 days before screening until randomization.
  • If the subjects are taking vitamin E > 400 IU/day, then it must be on a stable dose for at least 24 weeks prior to screening or, if a historical biopsy is used, at least 24 weeks prior to baseline liver biopsy until randomization.
  • Must provide written and agree to comply with the trial protocol.

Exclusion criteria

Exclusion Criteria:

  • Consumption of >2 units of alcohol per day (>14 units per week) if male and >1 units of alcohol per day (>7 units per week) if female for at least 12 consecutive weeks within 5 years before screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor)
  • History or presence of other concomitant liver diseases at screening:

    1. Chronic (HBV) or virus (HCV) infection (However, If the subject has been treated for the HCV infection and has been cured at least 5 years from screening, such subjects can be enrolled in the study)
    2. Primary biliary cholangitis (PBC)
    3. Primary sclerosing cholangitis (PSC)
    4. Definite liver disease or overlap syndrome
    5. Alcoholic liver disease
    6. Hemochromatosis
    7. Wilsons disease
    8. Alpha-1 antitrypsin deficiency
  • Subject with known cirrhosis, either based on histology, clinical criteria or any non-invasive diagnostic modality, within 24 weeks prior to the randomization.
  • Evidence of portal hypertension (low count, esophageal varices, ascites, history of hepatic encephalopathy, splenomegaly) at screening.
  • Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium glucose cotransporter- 2 (SGLT-2) inhibitors, and dipeptidyl peptidase 4 inhibitors (gliptins) unless stable for 120 days prior to screening or, if a historical is used, from 120 days prior to baseline liver biopsy until randomization.
  • Use of concurrent medications prior to screening including:

    1. Anti-NASH therapy(s) including S-adenosyl methionine (SAMe), ursodeoxycholic acid (UDCA), and obeticholic acid in the period from 90 days prior to screening or, if a historical biopsy is used, from 90 days prior to baseline liver biopsy until randomization. For resmetirom; 120 days prior to screening or if a historical biopsy is used, from 120 days prior to baseline liver biopsy until randomization.
    2. Antidiabetic mediation which may impact NASH histology including thiazolidinediones (pioglitazone, rosiglitazone) in the period from 90 days prior to screening or, if a historical biopsy is used, from 90 days prior to baseline liver biopsy until randomization.
    3. Immune modulatory agents including anti-TNF-α therapies (infliximab, adalimumab, etanercept) or anti-integrin therapy (namixilab) in the period from 28 days prior to screening or if a historical biopsy is used from 28 days prior to baseline liver biopsy until randomization.
    4. Any treatment or anticipated initiation (intended use for more than 14 consecutive days) of medications known to have an effect on steatosis (e.g. treatment with [topical and inhaled are allowed]), methotrexate, tamoxifen, valproic acid, amiodarone or tetracycline, estrogens in doses higher than used in oral , vitamin A, L-asparaginase, valproate, chloroquine, or antiretroviral drugs in the period from 28 days prior to screening or, if a historical biopsy is used, from 28 days prior to baseline liver biopsy until randomization.
    5. Treatment with orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion, or naltrexone alone, or in combination or any other medication, that could promote weight loss, in the opinion of the investigator, in the period from 28 days prior to screening or if a historical biopsy is used from 28 days prior to baseline liver biopsy until randomization.
  • Changing doses of statins (simvastatin, pitavastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, Fenofibrate) in the 90 days preceding screening until randomization.
  • Use of drugs that are known CYP2C8 inhibitors/substrate in the 28 days preceding screening until randomization.
  • History of liver transplant
  • Any weight reduction surgery in the 2 years prior to screening or planned during the study (weight reduction surgery is disallowed during the study), and malabsorptive weight loss surgery (Rouxen-Y or distal gastric bypass) at any time prior to screening.

Note: Lap banding, if the band has been removed >6 months before baseline liver biopsy, or intragastric balloon, if the balloon has been removed > 6 months before baseline liver biopsy, is allowed.

  • Type 1 diabetes mellitus
  • History of stomach or intestinal surgery or resection within the six months prior to screening that would potentially alter absorption and/or excretion of orally administered drugs as judged by the investigator.
  • Unstable cardiovascular disease, including:

    1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease) in the 90 days before screening and throughout the screening period; acute coronary syndrome in the 24 weeks before screening and throughout the screening period;
    2. acute myocardial infarction in the 90 days before screening and throughout the screening period; or heart failure of class (III - IV), worsening congestive heart failure, or coronary artery intervention, in the 24 weeks before screening and throughout the screening period.
    3. history of unstable cardiac dysrhythmias
    4. uncontrolled hypertension at screening
    5. stroke or in the 24 weeks before screening
  • History of myopathies or evidence of active muscle disease demonstrated by CPK ≥ 5 times at screening.
  • For subjects with elevated baseline , AST, or ALP; ALT, AST, or ALP exceeding by more than 50% at Visit 2 reading compared to Visit 1 Note: If the ALT, AST or ALP values at Visit 2 exceed by more than 50% from Visit 1, then a third value will be measured to assess for the trend. If the third value shows continued increase ≥ 10%, then subject is considered ineligible for randomization.
  • Any of the following laboratory values at screening:

    1. \<9 g/dL
    2. WBC count \<2.5 × 103/µL
    3. \<1.5 × 103/µL
    4. Platelets \<140 × 103/µL [if low platelet count is due to reasons other than liver disease as assessed by a hematologist, participants may be eligible if the platelet count is > 75 x 103/µL] as per investigator's discretion]
    5. ≥ 1.3 (in the absence of anticoagulants)
    6. Total > ULN except in Gilbert's syndrome. In subjects with known Gilbert's syndrome, direct bilirubin > 2 x ULN
    7. Albumin \<3.5 g/dL
    8. \<60 mL/min/1.73 m2
    9. ALP ≥ 2x ULN
    10. ALT or AST ≥ 250 U/L
  • Participation in any other therapeutic clinical study and on active treatment in the past 90 days of the screening.
  • History of benign or malignant bladder tumors, and/or hematuria or has current hematuria except due to a urinary tract infection.
  • History of in the past 5 years and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer.
  • Known allergy, sensitivity or intolerance to the study drug, comparator or formulation ingredients.
  • Pregnancy-related exclusions, including:

    1. Pregnant/lactating female (including positive pregnancy test at screening)
    2. Pregnancy should be avoided by male and female participants either by true abstinence or the use of an acceptable effective contraceptive measures for the duration of the study and for at least 1 month after the end of the study treatment
  • History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, , coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption)
  • Receiving an elemental diet or parenteral nutrition.
  • Chronic pancreatitis or pancreatic insufficiency.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    Saroglitazar Magnesium 2 mg

    Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.

    Drug: Saroglitazar Magnesium 2 mg

  • Experimental
    Saroglitazar Magnesium 4 mg

    Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.

    Drug: Saroglitazar Magnesium 4 mg

  • Placebo comparator
    Placebo

    Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.

    Drug: Placebo

Interventions

  • Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

    Also known as: Investigational Product

  • Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

    Also known as: Investigational Product

  • DrugPlacebo

    Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

    Also known as: Comparator Agent

06

What researchers measure

Primary outcomes

  1. Resolution of steatohepatitis with no worsening of fibrosis

    Resolution of steatohepatitis is defined as absent fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS of 0-1 for inflammation, 0 for ballooning, and any value for Steatosis

    Time frame: 52 Weeks/EOT

Secondary outcomes

  1. Improvement in liver fibrosis with no increase in NAS for ballooning, inflammation or steatosis

    Proportion of subjects achieving improvement in liver fibrosis (reduction of at least one stage) with no increase in NAS for ballooning, inflammation or steatosis

    Time frame: Week 52/EOT

  2. 2 points improvement in NAS

    Proportion of subjects with at least 2 points improvement in NAS at Week 52/EOT with at least 1-point improvement in either ballooning or inflammation and no worsening of liver fibrosis

    Time frame: Week 52/EOT

  3. Improvement in steatosis, ballooning, inflammation and fibrosis from liver biopsy

    Proportion of subjects with ≥1 point improvement in steatosis, ballooning, inflammation and fibrosis

    Time frame: Week 52/EOT

  4. Decrease in SAF score on liver biopsy

    Proportion of subjects with decrease in SAF score ≥2 combining hepatocellular inflammation and ballooning without worsening of fibrosis

    Time frame: Week 52/EOT

  5. Histological score changes in steatosis, ballooning, inflammation, and fibrosis

    Change from baseline in steatosis, ballooning, inflammation, and fibrosis

    Time frame: Week 52/EOT

  6. Change in liver enzyme parameters including (ALT, AST, ALP, GGT, total bilirubin, albumin)

    Change from baseline in liver enzyme parameters (ALT, AST, ALP, GGT, total bilirubin, albumin)

    Time frame: Week 52/EOT

  7. Change in non-invasive markers of steatosis

    Change from baseline in non-invasive markers of steatosis (Enhanced Liver Fibrosis \[ELF\] test, Fibrosis 4 \[FIB 4\], APRI \[AST to Platelet Ratio Index\], NFS \[NAFLD Fibrosis Score\], PRO-C3)

    Time frame: Week 52/EOT

  8. Change in n lipid parameters including (TG, LDLC, TC, HDL-C, non-HDL-C, VLDL-C

    Change from baseline in lipid parameters (TG, LDLC, TC, HDL-C, non-HDL-C, VLDL-C)

    Time frame: Week 52/EOT

  9. Change in body weight (any change from baseline)

    Change from baseline in body weight

    Time frame: Week 52/EOT

  10. Change in insulin resistance marker, HOMA-IR

    Change from baseline in insulin resistance marker (HOMA-IR)

    Time frame: Week 52/EOT

  11. Change in inflammatory markers including (CK-18 [M30], IL-6, CRP)

    Change from baseline in inflammatory markers (CK-18 \[M30\], IL-6, CRP)

    Time frame: Week 52/EOT

  12. Change in glucose homeostasis markers including (HbA1c, FPG)

    Change from baseline in glucose homeostasis markers (HbA1c, FPG)

    Time frame: Week 52/EOT

07

Study locations

129 sites
  • Zydus US032
    Birmingham, Alabama 35294, United States
  • Zydus US079
    Homewood, Alabama 35209, United States
  • Zydus US047
    Phoenix, Arizona 85013, United States
  • Zydus US025
    Tucson, Arizona 85712, United States
  • Zydus US087
    Tucson, Arizona 85712, United States
  • Zydus US029
    Tucson, Arizona 85724, United States
  • Zydus US118
    Chula Vista, California 91911, United States
  • Zydus US041
    Fresno, California 93720, United States
  • Zydus US111
    Gardena, California 90247, United States
  • Zydus US013
    Huntington Park, California 90255, United States
  • Zydus US065
    La Jolla, California 92037, United States
  • Zydus US094
    Lancaster, California 93534, United States
  • Zydus US080
    Long Beach, California 90808, United States
  • Zydus US090
    Long Beach, California 90815, United States
  • Zydus US022
    Los Angeles, California 90027, United States
  • Zydus US062
    Los Angeles, California 90033, United States
  • Zydus US023
    Murrieta, California 92563, United States
  • Zydus US052
    Orange, California 92868, United States
  • Zydus US012
    Panorama City, California 91402, United States
  • Zydus US039
    Aurora, Colorado 80045, United States
  • Zydus US122
    Clearwater, Florida 33761, United States
  • Zydus US057
    Fort Myers, Florida 33907, United States
  • Zydus US108
    Hallandale, Florida 33009, United States
  • Zydus US096
    Hialeah Gardens, Florida 33016, United States
  • Zydus US003
    Lakeland, Florida 33803, United States
  • Zydus US016
    Lakewood Rch, Florida 34211, United States
  • Zydus US125
    Largo, Florida 33777, United States
  • Zydus US001
    Maitland, Florida 32751, United States
  • Zydus US124
    Maitland, Florida 32751, United States
  • Zydus US007
    Miami, Florida 33014, United States
  • Zydus US024
    Miami, Florida 33135, United States
  • Zydus US034
    Miami, Florida 33136, United States
  • Zydus US038
    Miami, Florida 33136, United States
  • Zydus US121
    Miami, Florida 33155, United States
  • Zydus US054
    Miami, Florida 33173, United States
  • Zydus US098
    Miami Lakes, Florida 33016, United States
  • Zydus US099
    Naples, Florida 34102, United States
  • Zydus US081
    Ocala, Florida 34471, United States
  • Zydus US085
    Orlando, Florida 32806, United States
  • Zydus US104
    Port Orange, Florida 32127, United States
  • Zydus US004
    Winter Park, Florida 32789, United States
  • Zydus US107
    Dalton, Georgia 30720, United States
  • Zydus US113
    Gainesville, Georgia 30501, United States
  • Zydus US114
    Marietta, Georgia 30060, United States
  • Zydus US119
    Savannah, Georgia 31406, United States
  • Zydus US020
    Indianapolis, Indiana 46202, United States
  • Zydus US100
    West Des Moines, Iowa 50652, United States
  • Zydus US049
    Kansas City, Kansas 66160, United States
  • Zydus US071
    Houma, Louisiana 70363, United States
  • Zydus US014
    Marrero, Louisiana 70072, United States
  • Zydus US123
    West Monroe, Louisiana 71291, United States
  • Zydus US017
    Boston, Massachusetts 02215, United States
  • Zydus US092
    Chesterfield, Michigan 48047, United States
  • Zydus US019
    Wyoming, Michigan 49519, United States
  • Zydus US115
    Saint Paul, Minnesota 55101, United States
  • Zydus US074
    Columbia, Missouri 65201, United States
  • Zydus US120
    Kansas City, Missouri 64131, United States
  • Zydus US116
    Reno, Nevada 89511, United States
  • Zydus US077
    Sparta, New Jersey 07871, United States
  • Zydus US069
    Manhasset, New York 11030, United States
  • Zydus US066
    New York, New York 10033, United States
  • Zydus US018
    Asheville, North Carolina 28801, United States
  • Zydus US027
    Charlotte, North Carolina 28204, United States
  • Zydus US010
    Cincinnati, Ohio 45044, United States
  • Zydus US009
    Cincinnati, Ohio 45267-0595, United States
  • Zydus US035
    Cleveland, Ohio 44109, United States
  • Zydus US072
    Springboro, Ohio 45066, United States
  • Zydus US060
    Hershey, Pennsylvania 17033, United States
  • Zydus US053
    Philadelphia, Pennsylvania 19141, United States
  • Zydus US015
    Charleston, South Carolina 29401, United States
  • Zydus US030
    Charleston, South Carolina 29425, United States
  • Zydus US073
    Columbia, South Carolina 29204, United States
  • Zydus US075
    Greenwood, South Carolina 29646, United States
  • Zydus US112
    Summerville, South Carolina 29485, United States
  • Zydus US011
    Hermitage, Tennessee 37067, United States
  • Zydus US028
    Nashville, Tennessee 37232, United States
  • Zydus US002
    Arlington, Texas 76012, United States
  • Zydus US051
    Austin, Texas 78745, United States
  • Zydus US101
    Austin, Texas 78757, United States
  • Zydus US089
    Bellaire, Texas 77401, United States
  • Zydus US105
    Brownsville, Texas 78520, United States
  • Zydus US095
    Edinburg, Texas 78539, United States
  • Zydus US106
    Edinburg, Texas 78539, United States
  • Zydus US061
    Fort Worth, Texas 76104, United States
  • Zydus US067
    Houston, Texas 77030, United States
  • Zydus US109
    Houston, Texas 77030, United States
  • Zydus US005
    Houston, Texas 77058, United States
  • Zydus US110
    Houston, Texas 77079, United States
  • Zydus US117
    Katy, Texas 77084, United States
  • Zydus US031
    San Antonio, Texas 78215, United States
  • Zydus US103
    San Antonio, Texas 78222, United States
  • Zydus US036
    San Antonio, Texas 78229, United States
  • Zydus US102
    San Antonio, Texas 78229, United States
  • Zydus US043
    San Antonio, Texas 78234, United States
  • Zydus US008
    San Antonio, Texas 78240, United States
  • Zydus US078
    Waco, Texas 76712, United States
  • Zydus US076
    Wichita Falls, Texas 76301, United States
  • Zydus US088
    Ogden, Utah 84405, United States
  • Zydus US070
    Manassas, Virginia 20110, United States
  • Zydus US082
    Richmond, Virginia 23236, United States

Showing the first 100 of 129 sites across 4 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Sep 2025, 48 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 48 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2021
First posted
Aug 18, 2021
StartActual
Aug 18, 2021
Primary completionActual
Sep 12, 2025
CompletionActual
Sep 12, 2025
Results delay requested
Sep 9, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05011305
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Aug 18, 2021
Primary completion
Sep 12, 2025
Completion
Sep 12, 2025
Last update
Sep 21, 2026

Study contacts

Deven V. Parmar, MD, FCP
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion